Showing results (161-170 of 355) with videos related to
Sort By:
Pageof 36
Journal of the American Heart Association|February 23, 2024
Cost Effectiveness of Dapagliflozin for Heart Failure Across the Spectrum of Ejection Fraction: An Economic Evaluation Based on Pooled, Individual Participant Data From the DELIVER and DAPA-HF TrialsAnkeet S Bhatt, Muthiah Vaduganathan, Brian L Claggett, et al.Journal of the American College of Cardiology|August 27, 2025
Adiposity-Related Anthropometrics and Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Participant-Level Pooled Analysis of Randomized Clinical TrialsJohn W Ostrominski, Mats C Højbjerg Lassen, Jawad H Butt, et al.Journal of the American College of Cardiology|September 2, 2025
Natriuretic Peptides, Body Mass Index, and Clinical Outcomes in Heart Failure with Mildly Reduced or Preserved Ejection FractionJohn W Ostrominski, Brendon L Neuen, Brian L Claggett, et al.JAMA Cardiology|August 7, 2024
Rates of Sudden Death After Myocardial Infarction-Insights From the VALIANT and PARADISE-MI TrialsJames P Curtain, Marc A Pfeffer, Eugene Braunwald, et al.European Journal of Heart Failure|November 6, 2022
Association of post-vaccination adverse reactions after influenza vaccine with mortality and cardiopulmonary outcomes in patients with high-risk cardiovascular disease: the INVESTED trialAlexander Peikert, Brian L Claggett, KyungMann Kim, et al.Circulation|September 29, 2024
Efficacy and Safety of Finerenone Across the Ejection Fraction Spectrum in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the FINEARTS-HF TrialKieran F Docherty, Alasdair D Henderson, Pardeep S Jhund, et al.JACC. Heart Failure|April 15, 2025
Finerenone and New York Heart Association Functional Class in Heart Failure: The FINEARTS-HF TrialJohn W Ostrominski, Muthiah Vaduganathan, Brian L Claggett, et al.Circulation. Heart Failure|March 12, 2021
Cardiac and Noncardiac Disease Burden and Treatment Effect of Sacubitril/Valsartan: Insights From a Combined PARAGON-HF and PARADIGM-HF AnalysisLuis E Rohde, Brian L Claggett, Emil Wolsk, et al.JACC. Heart Failure|January 4, 2023
Blood Pressure and Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: DELIVERSenthil Selvaraj, Muthiah Vaduganathan, Brian L Claggett, et al.JACC. Heart Failure|August 26, 2025
Temporal Changes in Biomarkers, Functional Status, and Quality of Life Prior to Adverse Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection FractionHenri Lu, Brian L Claggett, Muthiah Vaduganathan, et al.Pageof 36